Research programme: cardiovascular drug targets - Myriad Genetics/Roche
Latest Information Update: 09 Nov 2006
At a glance
- Originator Myriad Pharmaceuticals; Roche
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cardiovascular disorders
Most Recent Events
- 09 Nov 2006 Discontinued - Preclinical for Cardiovascular disorders in USA (unspecified route)
- 19 Jan 2000 New profile
- 19 Jan 2000 Preclinical development for Cardiovascular disorders in USA (Unknown route)